Oxford Immunotec Limited, operating as Revvity | Reg: 04516079, was established in 2002 and maintains a continued focus on the development and provision of diagnostic and research tools. Currently, the company operates as a subsidiary within Revvity, specializing in the production and distribution of T-SPOT.TB tests and related immunological assays. These tests are crucial for detecting bovine tuberculosis (TB) infection, a significant public health concern. Revvity leverages Oxford Immunotec’s established expertise and intellectual property to offer a comprehensive suite of products and services. The company’s core offerings include rapid and reliable T-SPOT.TB testing, alongside custom antibody development and validation services. They cater to a diverse range of clients, including research institutions, pharmaceutical companies, and diagnostic laboratories globally. Revvity’s international presence is a key element of its strategy, with a commitment to expanding its operations across multiple regions. The company’s size is estimated to be mid-sized, reflecting a dedicated focus on innovation and quality within the immunological field. Revvity is currently a Worker (A rating) with Visa: Global Business Mobility, indicating a focus on international collaboration and professional development. The company’s key industry focus is related to diagnostics and biotechnology.

Oxford Immunotec Limited, operating as Revvity | Reg: 04516079, was established in 2002 and maintains a continued focus on the development and provision of diagnostic and research tools. Currently, the company operates as a subsidiary within Revvity, specializing in the production and distribution of T-SPOT.TB tests and related immunological assays. These tests are crucial for detecting bovine tuberculosis (TB) infection, a significant public health concern. Revvity leverages Oxford Immunotec’s established expertise and intellectual property to offer a comprehensive suite of products and services. The company’s core offerings include rapid and reliable T-SPOT.TB testing, alongside custom antibody development and validation services. They cater to a diverse range of clients, including research institutions, pharmaceutical companies, and diagnostic laboratories globally. Revvity’s international presence is a key element of its strategy, with a commitment to expanding its operations across multiple regions. The company’s size is estimated to be mid-sized, reflecting a dedicated focus on innovation and quality within the immunological field. Revvity is currently a Worker (A rating) with Visa: Global Business Mobility, indicating a focus on international collaboration and professional development. The company’s key industry focus is related to diagnostics and biotechnology.